Current treatment for fungal meningitis is fueling drug resistance

December 06, 2019

A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.

Published in the journal mBio, the findings highlight the need to develop new drugs and treatment regimens for the lethal brain infection, which kills around 180,000 people each year.

Cryptococcal meningitis is a leading cause of death among adults with HIV/AIDS in sub-Saharan Africa. In many parts of the world, the antifungal drug fluconazole is the only agent that is available for the initial treatment of the infection, despite considerable evidence that long-term outcomes are poor.

Drug resistance is thought to play a role in these poor outcomes, but solid data is currently lacking and a better understanding of the relationship between fluconazole exposure and the emergence of resistance has been needed.

In an experimental study in a novel hollow fibre model and mice, the relationship between drug exposure and both antifungal killing and the emergence of resistance to fluconazole was quantified. These results were then bridged to patients in a clinical study where patients with cryptococcal meningitis in Tanzania receiving fluconazole were studied.

The findings showed that fluconazole resistance is caused by duplication of the fungus' chromosomes and occurs while patients are on therapy. Simulations from mathematical models fitted to the patients' data suggested that only 12.8% of patients receiving fluconazole at the recommended 1,200 mg/day were completely free of the fungus after two weeks. Furthermore, 83.4% had a persistent subpopulation that was resistant to fluconazole. Preventing this would require significant dosage escalation of fluconazole beyond what is currently recommended.

William Hope, Professor of Therapeutics and Infectious Diseases at the University of Liverpool, said: "This study is unique in that it combines information from experimental models of cryptococcal meningitis with data from patients receiving fluconazole as monotherapy, which remains the norm in much of Africa, despite not being consistent with current treatment recommendations from the WHO.

"We've shown that the emergence of resistance is related to drug exposure and occurs with the use of clinically-relevant monotherapy regimens. Hence the only drug available to many patients in Africa is compromised by the ability of the fungus to develop resistance while the patient is taking fluconazole.

"Our findings underscore the urgent need for the development of new agents and combinations to reduce the global toll of cryptococcal meningitis."

Antimicrobial resistance is a growing threat and there has been a global push to address to develop new drugs. Led by Professor Hope, the University of Liverpool's Centre for Antimicrobial Pharmacodynamics provides state-of-the-art research facilities for PK/PD studies and offers preclinical and early phase clinical support to ensure new drugs are developed in a streamlined manner.
-end-
The study involved collaborators from St Georges, University of London, Duke University School of Medicine (USA) and the National Institute of Medical Research (Tanzania) and biotech company F2G Ltd.

Funding support was provided by the Medical Research Council, the Department for International Development and the Wellcome Trust.

University of Liverpool

Related Drug Resistance Articles from Brightsurf:

New drug that can prevent the drug resistance and adverse effects
A research team in Korea is garnering attention for having developed an anticancer drug that could potentially prevent drug resistance.

New drug combinations help overcome resistance to immunotherapy
A new study from researchers at the UCLA Jonsson Comprehensive Cancer Center helps explain how disruptions in genes can lead to the resistance to one of the leading immunotherapies, PD-1 blockade, and how new drug combinations could help overcome resistance to the anti-PD-1 therapy in a mechanistically-based way.

Drug overcomes chemotherapy resistance in ovarian cancer
In an international preclinical study, researchers found they could overcome chemotherapy resistance in clear cell ovarian cancer cell models using low doses of the drug 2-deoxy-D-glucose.

Engineers model mutations causing drug resistance
Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and 'second generation' approaches are needed.

Double success for University drug resistance research
Swansea University research into the threat posed by antifungal drug resistance has been highlighted in two prestigious international journals.

What fuels a 'domino effect' in cancer drug resistance?
KAIST researchers have identified mechanisms that relay prior acquired resistance to the first-line chemotherapy to the second-line targeted therapy, fueling a 'domino effect' in cancer drug resistance.

New flu drug drives drug resistance in influenza viruses
University of Wisconsin-Madison researchers examined the effects of baloxavir treatment on influenza virus samples collected from patients before and after treatment.

Resistance to last resort drug arose in patient over 3 weeks
French investigators have described development of resistance to one of the last resort therapies used to treat extremely drug-resistant Pseudomonas aeruginosa.

Cause of drug resistance in a drug resistance in intestinal tumors identified
Researchers clarify mechanisms that allow hard-to-treat cancers to develop, and have identified strategies that could lead to new therapies.

Engineered viruses could fight drug resistance
MIT biological engineers can program bacteriophages to kill different strains of E. coli by making mutations in the protein that the viruses use to bind to host cells.

Read More: Drug Resistance News and Drug Resistance Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.